New RNA vaccine shows promise in fight against malaria

NCT ID NCT06069544

Completed ⭐️ VACCINE ⭐️ Sponsor: BioNTech SE Source: ClinicalTrials.gov ↗

First seen Apr 18, 2026 · Last updated May 22, 2026 · Updated 4 times

Summary

This study tested an experimental RNA-based vaccine (BNT165e) designed to prevent malaria caused by the P. falciparum parasite. 163 healthy adults who had never had malaria received the vaccine, and researchers checked for side effects, immune response, and whether the vaccine could protect against infection. The goal is to develop a safe and effective vaccine to stop malaria.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MALARIA are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Locations

AMR Knoxville

Knoxville, Tennessee, 37909, United States
AMR Las Vegas

Las Vegas, Nevada, 89119, United States
AMR Tempe

Tempe, Arizona, 85281, United States
Clinical Trials of Texas

San Antonio, Texas, 78229, United States
University of Maryland, Center for Vaccine Development

Baltimore, Maryland, 21201, United States

Conditions

Explore the condition pages connected to this study.

MALARIA MALARIA